The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
"conservative" of course he has to say that, secretly he is wetting himself based on the upcoming share price, as am I. Bring it on!
Finger in the air although it does say in the note that they consider it conservative but a good starting position for negotiations
I am not sure how Raghuram Selvaraju converts a $25 ADR Target price into a £5 target price, given the USD is not on a par with GBP! I think he forgot to do the conversion to £4! I've emailed him about it....
Alastair. Any idea where Wainwright’s would get their “10%” from? This seems really conservative to me based on 40% greater accuracy of StemPrintER. Is that just a finger in the air Job, or would it be based on something?
Thanks.
don't know but HC Wainwright 'conservatively' put $280m on it based upon 10% of the genomic sale but stemprinter is then 40-50% more accurate. genomic (now exact sciences) has been around for 15 years so well entrenched so any pharma would want a big discount to reflect that (apart from exact sciences - who i don't think can take any risk on this and need the technology more than anyone). I think it is prudent for this board to be conservative as expectations can get out of hand so say $280m and TILS get a major funding boost for their blockbusters and shareholders get a special dividend that way we all win nicely . Don't forget how advanced the blockbusters are - the crohns disease one has already been shown to work in humans in a small study. I know nothing but 5 big pharmas know what TILS have and like it alot. that to me is a great reason to invest. STEM is an outrageous bonus whether it lists or gets sold.
From HC Wainwright..
And as a publicly-listed business, it is worth around 10% of the value of Genomic Health, the nearest competitor, HC Wainwright’s Raghuram Selvaraju reckons.
On that basis then its value should be in the region of US$280mln, which compares with Tiziana’s current market capitalisation of US$226mln.
“In our view, StemPrintER could begin trading as a separate entity well before the end of this year,” said Selvaraju in a note repeating his ‘buy’ recommendation and US$25 a share price target.
The whole STEM thing moved really quickly. I don't think even GC/Kunwar thought it was as good as it is. The study was done by Royal Marsden and European Centre for Oncology, who are titans in oncology, and i think the strength of this connection enabled TILS to get ASCO to showcase its poster (this is not an actual poster but a presentation - medical terms). May this year was the first results from stem then a few weeks later an intention to de-merge and then further results. This all happened over 4 weeks. We are now 6 weeks on and although a listing will take say to November to happen fully as a time consuming process, a sale can be much swifter and i truly think that TILS were shocked by the results so were pushed to demerge it by the level of buyer interest. Timing for a sale i would say october/november also but could be sooner as really there is not alot to sell and no complex staff etc it is merely IP around the algorithm. offers will move fast though but completion much later. I just cannot see how from the worlds biggest oncology conference, a test that usurps the best in the world by a mind boggling amount has not gained huge buyer interest in a world where pharma is gearing up for a major bull market. $300m to enter a market or cement your position in a market where the top test turned over that last year is ludicrous. have faith in kunwar and GC (they stand to gain the most financially which from a PI perspective is what you want) they are experienced in M&A. keep buying TILS and patience will be rewarded.
Agreed Steven on the strong buyer theory. That prime time interview on Bloomberg Sunday has surely tempted some big players to have a nibble...
solid day all round. AGM will be a on event like they always are but once gone it will then make way for STEM news which is where the short term action is on TILS. Since March GC and Kunwar have been very active on the PR side of the business obviously culminating in the bloomberg piece on sunday. crucially as business leaders they get the PR angle is crucial so expect them to release STEM swiftly not least so that the big pharmas who are currently battling it out to buy actually sharpen their pencils and get a move on.
Maybe.
I think some ATM's are going through - just looking at the price action the Offers just dropped aggressively..
Market taken them very well, strong buyer lerking in the background on AIM...
$9.80 paid on the Nasdaq - Will it breach $10